Indaptus (INDP) Surges 23% on Clinical Trial Optimism and Capital Raise Momentum

Summary
• Indaptus Therapeutics (INDP) surges 23% intraday, hitting $3.68 after opening at $2.90
• Clinical update reveals partial response in urothelial cancer patient with Decoy20 monotherapy
• $5.7M capital raise through convertible notes strengthens balance sheet
• Reverse stock split in June 2025 aims to enhance Nasdaq compliance and attract investors

Indaptus Therapeutics (INDP) is experiencing a dramatic intraday rally, surging 23% to $3.68 as of 7:34 PM EDT. The stock’s sharp move follows a clinical update highlighting a partial response in a urothelial cancer patient and a recent $5.7 million capital raise. With a 52-week high of $58.24 and a 52-week low of $2.22, the stock’s volatility underscores its speculative nature and reliance on clinical milestones.

Clinical Trial Optimism and Capital Raise Fuel Surge
Indaptus’ 23% intraday surge is driven by two key catalysts: a clinical update on Decoy20’s partial response in a urothelial cancer patient and a $5.7 million capital raise. The clinical update, announced on September 4, 2025, reported a reduction in liver metastases for a patient previously treated with anti-PD-1 therapy, despite subsequent disease progression. This partial response, combined with the initiation of combination therapy trials with tislelizumab, has reignited investor optimism. Additionally, the company’s July 2025 capital raise through convertible notes and warrants has bolstered its balance sheet, addressing liquidity concerns and supporting ongoing clinical trials.

Technical Analysis and ETF Strategy for Volatile Biotech Play
• MACD: -0.806 (Signal Line: -1.014, Histogram: 0.208) – Indicates potential bullish momentum
• RSI: 55.26 – Suggests neutral to overbought territory
• Bollinger Bands: Upper (4.55), Middle (3.04), Lower (1.53) – Price near upper band, signaling overbought conditions
• 200D MA: 2.85 – Current price above 200D MA, suggesting short-term strength

Indaptus’ technical profile suggests a high-volatility trade. The stock is trading near the upper Bollinger Band, with RSI approaching overbought levels, while the MACD histogram shows positive divergence. Key support levels include the 30D MA at $2.49 and the 200D MA at $2.85. A break above $4.55 (upper Bollinger Band) could trigger a parabolic move, while a retest of $2.88 (intraday low) may offer a short-term entry. Given the absence of listed options, investors should focus on ETFs like XBI (Biotech Select Sector SPDR) or IBB (iShares Genomic Immunology ETF) for sector exposure. The biotech sector’s mixed performance, led by AMGN (up 6.3%), highlights the need for caution in this high-beta space.

Backtest Indaptus Stock Performance
Indaptus Therapeutics (INDP) has shown significant growth potential, particularly after a notable 23% intraday surge in 2025. To evaluate its performance, let's examine the key milestones and corresponding impact on stock price:1. FDA Clearance of IND Application (May 2022): - The FDA cleared Indaptus' Investigational New Drug (IND) application for a Phase 1 clinical trial of Decoy20. - Following this news, INDP surged by 37.20% to $3.43 premarket on May 19, 2022.2. Corporate Update and Financial Results (Nov 2022): - Indaptus reported financial results for Q3 2022, highlighting preparations for the launch of the Phase 1 trial of Decoy20. - Despite the focus on clinical trial preparations, the stock continued to show potential, reflecting investor confidence in the company's advancements.The 23% intraday surge in 2025 can be attributed to the FDA's announcement of the IND application clearance. This milestone not only validated Indaptus' research but also signaled a significant step towards bringing their innovative therapy to clinical trials. As a result, investor confidence increased, leading to a substantial surge in stock price. The company's continued progress in clinical trial preparations and positive preclinical model results have likely contributed to the sustained positive sentiment in the stock's performance.{"chart":"","subchart":"","query":"INDP Percentage Change","visualType":"line","legend":"False","title":"Indaptus Therapeutics Stock Performance","xAxis":"2022-01-01","yAxis":"-20.0","width":"100%","height":"100%","dataset":[{"data":[-20.0], "label": "INDP", "lineWidth": 2.0}]}]}

Position for Next Catalyst: Clinical Data or Capital Raise
Indaptus’ 23% surge reflects renewed optimism around Decoy20’s clinical potential and improved liquidity. However, the stock’s extreme volatility and lack of profitability (P/E: -0.2) demand a disciplined approach. Investors should monitor the 30D MA ($2.49) as a critical support level and the 200D MA ($2.85) for trend confirmation. A sustained break above $4.55 could validate bullish sentiment, while a drop below $2.88 may signal a short-term pullback. With AMGN (up 6.3%) leading the biotech sector, position sizing and stop-loss placement are critical. For aggressive traders, a long position in XBI or IBB offers sector exposure, while cash-secured puts could capitalize on potential dips. Watch for Q4 clinical data or further capital raises to determine the stock’s trajectory.